

Contents

Preface *XIII*

List of Contributors *XV*

1	Lipidomics Perspective: From Molecular Lipidomics to Validated Clinical Diagnostics	1
	<i>Kim Ekroos</i>	
1.1	Introduction	1
1.2	Hierarchical Categorization of the Analytical Lipid Outputs	2
1.2.1	Lipid Class	3
1.2.2	Sum Compositions	4
1.2.3	Molecular Lipids	5
1.2.4	Structurally Defined Molecular Lipids	6
1.3	The Type of Lipid Information Delivers Different Biological Knowledge	7
1.4	Untying New Biological Evidences through Molecular Lipidomic Applications	9
1.5	Molecular Lipidomics Approaches Clinical Diagnostics	11
1.6	Current Roadblocks in Lipidomics	14
1.7	Conclusions	16
	References	16
2	Lipids in Cells	21
	<i>Kai Simons, Christian Klose, and Michal Surma</i>	
2.1	Introduction	21
2.2	Basis of Cellular Lipid Distribution	22
2.3	Lipid Distribution by Nonvesicular Routes	23
2.4	Lipids in Different Cell Types	24
2.5	Functional Implications of Membrane Lipid Composition	26
2.6	Outlook: Collectives and Phase Separation	29
	References	30

3	High-Throughput Molecular Lipidomics	35
	<i>Marcus Ståhlman, Jan Borén, and Kim Ekroos</i>	
3.1	Introduction	35
3.2	Lipid Diversity	35
3.3	Function of Molecular Lipids	38
3.4	Automated Sample Preparation	39
3.5	Different Approaches to Molecular Lipidomics	41
3.5.1	Untargeted versus Targeted Approaches	41
3.5.2	Shotgun Lipidomics	42
3.5.3	Analytical Validation of the Shotgun Approach	44
3.5.4	Targeted LC-MS Lipidomics	45
3.6	Data Processing and Evaluation	46
3.7	Lipidomic Workflows	47
3.8	Conclusions and Future Perspectives	48
	References	49
4	Multidimensional Mass Spectrometry-Based Shotgun Lipidomics	53
	<i>Hui Jiang, Michael A. Kiebish, Daniel A. Kirschner, and Xianlin Han</i>	
4.1	Introduction	53
4.2	Multidimensional Mass Spectrometry-Based Shotgun Lipidomics	53
4.2.1	Intrasource Separation	54
4.2.2	The Principle of Multidimensional Mass Spectrometry	55
4.2.3	Variables in Multidimensional Mass Spectrometry	57
4.2.3.1	Variables in Fragment Monitoring by Tandem MS Scans	57
4.2.3.2	Variables Related to the Infusion Conditions	57
4.2.3.3	Variables under Ionization Conditions	57
4.2.3.4	Variables under Collision Conditions	58
4.2.3.5	Variables Related to the Sample Preparations	58
4.3	Application of Multidimensional Mass Spectrometry-Based Shotgun Lipidomics for Lipidomic Analysis	59
4.3.1	Identification of Lipid Molecular Species by 2D Mass Spectrometry	59
4.3.1.1	Identification of Anionic Lipids	59
4.3.1.2	Identification of Weakly Anionic Lipids	59
4.3.1.3	Identification of Charge Neutral but Polar Lipids	59
4.3.1.4	Identification of Sphingolipids	59
4.3.1.5	The Concerns of the MDMS-Based Shotgun Lipidomics for Identification of Lipid Species	61
4.3.2	Quantification of Lipid Molecular Species by MDMS-Based Shotgun Lipidomics	61
4.3.2.1	The Principle of Quantification of Individual Lipid Species by MS	62
4.3.2.2	Quantification by Using a Two-Step Procedure in MDMS-Based Shotgun Lipidomics	62
4.3.2.3	Quantitative Analysis of PEX7 Mouse Brain Lipidome by MDMS-Based Shotgun Lipidomics	63
4.4	Conclusions	66
	References	68

5	Targeted Lipidomics: Sphingolipidomics	73
	<i>Ying Liu, Yanfeng Chen, and M. Cameron Sullards</i>	
5.1	Introduction	73
5.2	Sphingolipids Description and Nomenclature	75
5.3	Sphingolipids Analysis via Targeted LC-MS/MS	76
5.3.1	Sphingolipid Internal Standards	77
5.3.2	Biological Sample Preparation and Storage	78
5.3.3	Sphingolipid Extraction Protocol	79
5.3.4	Liquid Chromatography	81
5.3.4.1	LCBs and Cer1P	83
5.3.4.2	Cer, HexCer, LacCer, SM, ST, and Cer1P	84
5.3.4.3	Separation of GlcCer and GalCer	85
5.3.5	Mass Spectrometry	85
5.3.5.1	Electrospray Ionization	85
5.3.5.2	Tandem Mass Spectrometry	86
5.3.5.3	Multiple Reaction Monitoring	88
5.3.6	Generation of Standard Curves	89
5.3.7	Data Analysis	90
5.3.8	Quality Control	90
5.4	Applications of Sphingolipidomics in Biology and Disease	91
5.4.1	LC-MS/MS	91
5.4.2	Transcriptomic Guided Tissue Imaging Mass Spectrometry	92
5.5	Conclusions	94
	References	94
6	Structural Lipidomics	99
	<i>Todd W. Mitchell, Simon H.J. Brown, and Stephen J. Blanksby</i>	
6.1	Introduction	99
6.2	Lipid Structure	100
6.3	Structural Analysis of Lipids by Mass Spectrometry	100
6.4	<i>sn</i> Position	105
6.5	Double Bond Position	107
6.5.1	Untargeted Fragmentation	108
6.5.2	Targeted Fragmentation	115
6.6	Double Bond Stereochemistry	122
6.7	Conclusions	123
	References	124
7	Imaging Lipids in Tissues by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry	129
	<i>Robert M. Barkley, Joseph A. Hankin, Karin A. Zemski Berry, and Robert C. Murphy</i>	
7.1	Introduction	129
7.2	Sample Preparation	130
7.3	Matrix	131
7.3.1	Techniques for Matrix Application	131

7.3.2	Matrix Compounds	133
7.4	Instrumentation	134
7.4.1	Lasers and Rastering	134
7.4.2	Ion Formation	136
7.4.3	Mass Analyzers and Ion Detection	137
7.5	Data Processing	139
7.6	Conclusions	141
	References	142
8	Lipid Informatics: From a Mass Spectrum to Interactomics	147
	<i>Christer S. Ejsing, Peter Husen, and Kirill Tarasov</i>	
8.1	Introduction	147
8.2	Lipid Nomenclature	148
8.3	Basic Properties of Lipid Mass Spectrometric Data	151
8.3.1	Mass Spectrum	152
8.3.2	Mass Accuracy and Reproducibility	154
8.3.3	Isotopes, Deisotoping, and Isotope Correction	154
8.4	Data Processing	158
8.4.1	<i>De Novo</i> Lipid Identification	159
8.4.2	Targeted Export of Lipidomic Data	161
8.4.3	Normalization of Lipidomic Data	162
8.5	Lipidomic Data Mining and Visualization	165
8.5.1	Comparative Lipidomics	165
8.5.2	Multivariate Data Analysis	166
8.5.3	Lipidomics in Biomarker Research	166
8.6	Lipidomic Data Integration	168
8.7	Conclusions and Future Perspectives	169
	References	170
9	Lipids in Human Diseases	175
	<i>M. Mobin Siddique and Scott A. Summers</i>	
9.1	Introduction	175
9.2	Obesity	176
9.3	Dyslipidemia	177
9.4	Diabetes	177
9.5	Cardiovascular Disorders	179
9.6	Hereditary Sensory Neuropathy	181
9.7	Neurodegeneration	182
9.8	Cancer	184
9.9	Lysosomal Storage Disorders	186
9.10	Cystic Fibrosis	187
9.11	Anti-Inflammatory Lipid Mediators	188
9.12	Conclusions	188
	References	189

10	Lipidomics in Lipoprotein Biology	197
	<i>Marie C. Lhomme, Laurent Camont, M. John Chapman, and Anatol Kontush</i>	
10.1	Introduction	197
10.2	Metabolism of Lipoproteins	198
10.3	Lipoproteinomics in Normolipidemic Subjects	200
10.3.1	Phospholipids	202
10.3.1.1	Phosphatidylcholine	202
10.3.1.2	Lysophosphatidylcholine	202
10.3.1.3	Phosphatidylethanolamine	203
10.3.1.4	Phosphatidylethanolamine Plasmalogens	203
10.3.1.5	Phosphatidylinositol, Phosphatidylserine, Phosphatidylglycerol, and Phosphatidic Acid	203
10.3.1.6	Cardiolipin	203
10.3.1.7	Isoprostane-Containing PC	203
10.3.2	Sphingolipids	203
10.3.2.1	Sphingomyelin	204
10.3.2.2	Lysosphingolipids	204
10.3.2.3	Ceramide	204
10.3.2.4	Minor Sphingolipids	204
10.3.3	Sterols	205
10.3.4	Cholesteryl Esters	205
10.3.5	Triacylglycerides	205
10.3.6	Minor Lipids	205
10.4	Altered Lipoproteinomics in Dyslipidemia	206
10.4.1	Phospholipids	206
10.4.1.1	Phosphatidylcholine	206
10.4.1.2	Lysophosphatidylcholine	207
10.4.1.3	Phosphatidylethanolamine	208
10.4.1.4	Phosphatidylethanolamine Plasmalogens	208
10.4.1.5	Phosphatidylinositol	208
10.4.1.6	Isoprostane-Containing PC	208
10.4.2	Sphingolipids	209
10.4.2.1	Sphingomyelin	209
10.4.2.2	Lysosphingolipids: S1P and Dihydro S1P	209
10.4.2.3	Ceramide	210
10.4.3	Free Cholesterol	210
10.4.4	Cholesteryl Esters	210
10.4.5	Triacylglycerides	210
10.4.6	Minor Lipids	211
10.4.6.1	Nonesterified Fatty Acids	211
10.4.6.2	Ganglioside GM1	211
10.4.6.3	Oxidized Lipids	211
10.5	Conclusions	211
	References	212

11	Mediator Lipidomics in Inflammation Research	219
	<i>Makoto Arita, Ryo Iwamoto, and Yosuke Isobe</i>	
11.1	Introduction	219
11.2	PUFA-Derived Lipid Mediators: Formation and Action	219
11.3	LC-ESI-MS/MS-Based Lipidomics	222
11.3.1	Sample Preparation	222
11.3.2	LC-ESI-MS/MS Analysis	223
11.4	Mediator Lipidomics in Inflammation and Resolution	226
11.5	Conclusion and Future Perspective	230
	References	230
12	Lipidomics for Elucidation of Metabolic Syndrome and Related Lipid Metabolic Disorder	233
	<i>Ryo Taguchi, Kazutaka Ikeda, and Hiroki Nakanishi</i>	
12.1	Introduction	233
12.2	Basic Strategy of Lipidomics for Elucidating Metabolic Changes of Lipids at the Level of their Molecular Species in Metabolic Syndrome and Related Diseases	234
12.3	Analytical Systems by Mass Spectrometry in Lipidomics	235
12.3.1	LC-MS and LC-MS/MS Analyses for Global Detection of Phospholipids and Triglycerides	235
12.3.2	Infusion Analysis with Precursor Ion and Neutral Loss Scanning	236
12.3.3	Targeted Analysis by Multiple Reaction Monitoring for Oxidized Lipids and Lipid Mediators by LC-MS/MS on Triple-Stage Quadrupole Mass Spectrometers	236
12.4	Lipidomic Data Processing	236
12.4.1	Strategy of Lipid Search	236
12.4.2	Application and Identification Results of “Lipid Search”	237
12.5	Analysis of Lipids as Markers of Metabolic Syndrome	239
12.5.1	Oxidized Phospholipids	239
12.5.1.1	Application for Myocardial Ischemia-Reperfusion Model	239
12.5.2	Bioactive Acidic Phospholipids	240
12.5.2.1	Lysophosphatidic Acid	240
12.5.2.2	Phosphoinositides	241
12.5.3	Oxidative Triglycerides	241
12.5.3.1	Application for Mouse White Adipose Tissue	242
12.5.4	Sphingolipids	244
12.5.4.1	Application for Sphingolipid Metabolism	244
12.6	Direct Detection of Lipid Molecular Species in Specific Tissue Domains by Disease-Specific Changes	245
12.7	Conclusions	245
	References	246

13	Lipidomics in Atherosclerotic Vascular Disease	251
	<i>Minna T. Jänis and Reijo Laaksonen</i>	
13.1	Introduction	251
13.2	Lipids and Atherosclerotic Vascular Disease	253
13.2.1	Lipoproteins	254
13.2.2	Atherosclerotic Plaque	255
13.2.3	Molecular Lipids	256
13.2.3.1	Eicosanoids	256
13.2.3.2	Sphingolipids and Cholesterol	257
13.2.3.3	Phospholipids	258
13.2.4	Animal Models of Atherosclerotic Research	259
13.3	Diagnostics and Treatment	260
13.3.1	Diagnostic Biomarkers of Atherosclerosis	260
13.3.2	Lipidomics in Efficacy and Safety Measurements	261
13.4	Conclusions	262
	References	263
14	Lipid Metabolism in Neurodegenerative Diseases	269
	<i>Lynette Lim, Guanghou Shui, and Markus R. Wenk</i>	
14.1	Introduction	269
14.1.1	Brain Lipids	270
14.1.2	Mass Spectrometry of Brain Lipids	272
14.2	Alzheimer's Disease	275
14.2.1	Cholesterol and Cholesterol Esters	276
14.2.2	Sulfatides	277
14.2.3	Plasmalogen Ethanolamines	277
14.2.4	Phospholipases	278
14.2.4.1	Phospholipase A2	278
14.2.4.2	Phospholipase C and Phospholipase D	279
14.3	Parkinson's Disease	281
14.3.1	Cerebrosides	283
14.3.2	Coenzyme Q	284
14.3.3	Endocannabinoids	285
14.4	Conclusions	287
	References	288
15	The Tumor Mitochondrial Lipidome and Respiratory Bioenergetic Insufficiency	297
	<i>Thomas N. Seyfried, Jeffrey H. Chuang, Lu Zhang, Xianlin Han, and Michael A. Kiebish</i>	
15.1	Introduction	297
15.1.1	Lipidomic Abnormalities in Tumor Mitochondria	298
15.2	Cardiolipin and Electron Transport Chain Abnormalities in Mouse Brain Tumor Mitochondria	299

15.3	Complicating Influence of the <i>in vitro</i> Growth Environment on Cardiolipin Composition and Energy Metabolism	307
15.4	Bioinformatic Methods to Interpret Alterations in the Mitochondrial Lipidome	311
15.5	Conclusions	314
	References	314
16	Lipidomics for Pharmaceutical Research	319
	<i>Yoshinori Satomi</i>	
16.1	Introduction	319
16.2	Biomarkers for Pharmaceutical Research	320
16.3	Strategy for Biomarker Discovery	321
16.4	Conclusions	326
	References	326
	Index	329